Disparities in Medication Use for Criminal Justice System-Referred Opioid Use Disorder Treatment.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Medical Association Country of Publication: United States NLM ID: 101769500 Publication Model: Electronic Cited Medium: Internet ISSN: 2689-0186 (Electronic) Linking ISSN: 26890186 NLM ISO Abbreviation: JAMA Health Forum Subsets: MEDLINE
    • Publication Information:
      Original Publication: Chicago, IL : American Medical Association, [2020]-
    • Subject Terms:
      Opioid-Related Disorders*/drug therapy ; Opioid-Related Disorders*/epidemiology ; Criminal Law* ; Opiate Substitution Treatment*/statistics & numerical data; Humans ; Cross-Sectional Studies ; Male ; Female ; Adult ; Middle Aged ; Healthcare Disparities ; United States/epidemiology ; Referral and Consultation ; Young Adult
    • Abstract:
      Importance: Individuals with opioid use disorder (OUD) and criminal justice system involvement experience high rates of overdose death. Historical data point to limited use of medications for opioid use disorder (MOUD) in criminal justice system-referred treatment for OUD as playing a role. However, how MOUD use among those referred to treatment by the criminal justice system has changed relative to other referral sources over time is still unclear, as well as how it varies across states.
      Objective: To examine disparities in the use of MOUD between individuals referred to treatment by the criminal justice system compared to other referral sources over time.
      Design, Setting, and Participants: This cross-sectional study included admissions to specialty substance use treatment facilities for OUD in the national Treatment Episodes Dataset-Admissions from 2014 to 2021. Logistic regression models were used to examine trends in the probability of MOUD use among individuals with and without criminal justice referrals for OUD treatment, as well as any differential trends by state. The data were analyzed from September 2023 to August 2024.
      Main Outcome and Measure: The main outcome was the probability that treatment for individuals with OUD included MOUD.
      Results: A total of 3 235 445 admissions were analyzed in the study data. Among individuals referred to OUD treatment by the criminal justice system, the probability that treatment included MOUD increased by 3.42 percentage points (pp) (95% CI, 3.37 pp to 3.47 pp) annually from 2014 to 2021. This was faster than the increase in the probability of MOUD use for noncriminal justice-referred admissions (2.49 pp [95% CI, 2.46 pp to 2.51 pp) and reduced, but did not eliminate, disparities in MOUD use between individuals with and without criminal justice system-referred treatment. In 2021, only 33.6% of individuals in criminal justice system-referred treatment received MOUD, 15.6 pp lower than for individuals referred to treatment by other sources. Trends in the probability of MOUD use varied substantially for individuals in criminal justice system-referred treatment across states, but very few experienced enough growth to eliminate this disparity.
      Conclusions and Relevance: The results of this cross-sectional study suggest that targeted efforts to address persistent disparities in MOUD use among those with OUD and criminal justice system involvement are needed to address the poor health outcomes experienced by this population.
    • References:
      Int J Drug Policy. 2007 Dec;18(6):464-74. (PMID: 18061872)
      Addiction. 2020 Dec;115(12):2329-2338. (PMID: 32267585)
      Drug Alcohol Depend. 2022 Mar 1;232:109291. (PMID: 35033953)
      JAMA Psychiatry. 2021 Sep 1;78(9):979-993. (PMID: 34076676)
      JAMA Intern Med. 2018 Sep 1;178(9):1153-1154. (PMID: 30073242)
      Epidemiol Rev. 2018 Jun 1;40(1):121-133. (PMID: 29733373)
      JAMA. 2021 Jul 13;326(2):154-164. (PMID: 34255008)
      Health Aff (Millwood). 2017 Dec;36(12):2046-2053. (PMID: 29200340)
      JAMA Netw Open. 2021 Dec 1;4(12):e2138807. (PMID: 34905010)
      Health Aff (Millwood). 2021 Apr;40(4):562-570. (PMID: 33819101)
      J Subst Use Addict Treat. 2023 Apr;147:208950. (PMID: 36804347)
      N Engl J Med. 2023 May 11;388(19):1779-1789. (PMID: 37163624)
      Addiction. 2012 Mar;107(3):501-17. (PMID: 21955033)
      Int J Drug Policy. 2020 Jul;81:102768. (PMID: 32446130)
      J Subst Abuse Treat. 2019 Apr;99:32-43. (PMID: 30797392)
      Health Serv Res. 2012 Feb;47(1 Pt 1):255-74. (PMID: 22091735)
      N Engl J Med. 2007 Jan 11;356(2):157-65. (PMID: 17215533)
      Cochrane Database Syst Rev. 2013 Dec 19;(12):CD010862. (PMID: 24353217)
      Health Aff (Millwood). 2020 May;39(5):740-746. (PMID: 32364856)
      Health Justice. 2021 Jul 24;9(1):17. (PMID: 34304335)
      Subst Abuse Rehabil. 2016 Apr 27;7:27-40. (PMID: 27217808)
      J Subst Use Addict Treat. 2023 Apr;147:208971. (PMID: 36821990)
      Drug Alcohol Depend. 2020 Aug 1;213:108088. (PMID: 32498032)
    • Publication Date:
      Date Created: 20240906 Date Completed: 20240906 Latest Revision: 20240910
    • Publication Date:
      20240910
    • Accession Number:
      PMC11380100
    • Accession Number:
      10.1001/jamahealthforum.2024.2807
    • Accession Number:
      39240579